赖增伟

男， 江南大学， 教授/研究员/教授级高工或同等级别

学习/工作经历

2004.9-2008.6 河北师范大学，化学专业，本科
2008.9-2011.6 云南大学（与中科院昆明植物研究所联合培养），有机化学专业，硕士
2011.9-2014.6 中国药科大学（中科院上海有机所联合培养），药物化学专业，博士
2014.8-2016.1 香港科技大学，博士后
2016.2-2018.12中山大学药学院，特聘研究员
2019.1-2019.09中科院上海药物研究所，助理研究员
2019.10-2022.02 中科院上海药物研究所，副研究员
2022.3至今 江南大学生命科学与健康工程学院，研究员，博士生导师

研究领域和兴趣

有机合成，药物化学

主要业绩

赖增伟研究员长期从事基于天然产物的创新药物研究及有机合成新方法学研究。在创新药物研究方面，致力于从天然产物中发掘结构新颖的苗头化合物，通过全合成及靶向性结构优化，围绕肿瘤、肝纤维化、肺动脉高压等重大慢性疾病，已成功发现多个具有成药性的先导化合物。在有机合成新方法方面，聚焦于含氮杂环结构的创制，发展了多种基于含氮偶极子的环加成反应，实现了对环加成反应立体选择性的有效调控，高效构建了一系列结构新颖、具有三维立体特征的含氮杂环骨架，丰富了杂环化合物的结构类型，并在此基础上对相关杂环分子进行了系统的生物活性发掘，发现了一批具有开发潜力的活性先导分子。迄今为止，以第一和通讯作者身份在包括Acta. Pharm. Sin. B、J. Med. Chem.、Chem. Sci.、Eur. J. Med. Chem.、Chin. Chem. Lett.、Org. Lett.、Chin. J. Chem.等药学和化学领域期刊发表SCI论文20余篇，授权发明专利6项。任《Pharmaceutical Science Advances》青年编委会委员，指导研究生获2026年江南大学校级优秀硕士毕业论文。

代表成果

1) Ting Xiao, Feng Lv, Weiwei Xia, Shiru Li, Yang Ma, Anhui Liao, Zhe Liu, Yan Ding, and Zengwei Lai*. Organocatalytic Enantioselective [3+2] Cycloaddition of para-Quinamines with Cyclic N-Sulfonyl Ketimines: Access to Imidazolidine-Fused Benzosultam Derivatives. Chin. J. Chem. 2026, 44, 3327-3333.
2) Yan Ding, Feng Lv, Yue Chen, Zhe Liu, Yang Ma, Shiru Li, Dejing Yin, Jian Wen, Yong Rao*, Ling Huang*, Zengwei Lai*. Brønsted acid-catalyzed asymmetric [3 + 3] cyclization of para-quinamines: access to 6/6/6/6-fused tetracyclic 1,2,4-triazinanes. Chin. Chem. Lett. 2026, 37, 112288.
3) Zhe Liu, Yan Ding, Mingbin Chen, Feng Lv, Ting Xiao, Wen-Bin Liu, Bingrui Wan, Ling Huang, Yong Rao*, Zengwei Lai*. Cycloaddition of para-Quinamines and para-Quinols with C, N-cyclic azomethine Imines: Access to 6/5/6/6-Fused Tetracyclic Pyrazolidines. Org. Lett. 2025, 27(24), 6257-6263.
4) Wenbin Liu, Xiaoying Xie, Haonan Zong, Yaxu Li, Yan Ding, Zhe Liu, Bingrui Wan, Ting Xiao, Feng Lv, Chunlei Tang, Lei Yu*, Ping Wang*, Zengwei Lai*. Design, Synthesis and Biological Evaluation of Triazolothiadiazole Derivatives as FSP1 Inhibitors for Sensitizing Cancer Cells to Ferroptosis. Eur. J. Med. Chem. 2025, 293, 117737.
5) Kai-Long Ji, Wei Liu, Wei-Hang Yin, Xiang-Rong Kong, Hong-Hong Xu, Zeng-Wei Lai*, Jing-Ya Li*, Jian-Min Yue*. A new class of potent liver injury protective compounds: Structural elucidation, total synthesis and bioactivity study. Acta. Pharm. Sin. B 2023, 13(8), 3414-3415.
6) Kai-Wen Hu, Xiao You, Jin-Zheng Wang, Xiaoan Wen, Hongbin Sun*, Qing-Long Xu*, Zengwei Lai*. Chiral Phosphoric Acid Catalyzed Asymmetric Desymmetrization of para-Quinamines with Isocyanates: Access to Functionalized Imidazolidin-2-one Derivatives.-¬ Org. Lett. 2021, 23(20), 7873-787¬7.
7) Zengwei Lai#, Renwei Zhang#, Qiang Feng, Jianwei Sun*. 3-Aminooxetanes: Versatile 1,3-Amphoteric Molecules for Intermolecular Annulation Reactions. Chem. Sci. 2020, 11, 9945-9949.
8) Chen Zhang, Qian Zhou, Xu-Nian Wu, Ya-Dan Huang, Jie Zhou, Zengwei Lai*, Yinnuo Wu*, Hai-Bin Luo. Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer’s disease. J. Enzym. Inhib. Med. Chem. 2018, 33(1), 260-270.
9) Zeng-Wei Lai, Chuan Liu, Hongbin Sun*, Shu-Li You*. Asymmetric Synthesis of 3-Allyloxindoles and 3-Allenyloxindoles by Scandium(III)-catalyzed Claisen Rearrangement Reactions. Chin. J. Chem. 2017, 35(10), 1512-1516.
10) Zengwei Lai, Zhaobin Wang, Jianwei Sun*. Organocatalytic Asymmetric Nucleophilic Addition to ortho-Quinone Methides by Alcohols. Org. Lett. 2015, 17(24), 6058-6061.
11) Zeng-Wei Lai, Chunhong Li, Jun Liu, Lingyi Kong, Xiaoan Wen*, Hongbin Sun*. Discovery of Highly Potent DPP-4 Inhibitors by Hybrid Compound Design Based on Linagliptin and Alogliptin. Eur. J. Med. Chem. 2014, 83, 547-560.
12) Yu-Rong Yang*, Zeng-Wei Lai, Liang Shen, Jiu-Zhong Huang, Xing-De Wu, Jun-Lin Yin and Kun Wei. Total Synthesis of (-)-8-Deoxyserratinine via an Efficient Helquist Annulation and Double N-Alkylation Reaction. Org. Lett. 2010, 12(15), 3430-3433.

*以上信息由高级会员个人更新和维护。